Trial Profile
1-2 Phase of Safety and Efficacy of Patient Intraneural Injections of VEGF165 Plasmid Gene Therapy on Regeneration After Total Severance or Disruption of the Entire Nerve Fiber
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Sep 2017
Price :
$35
*
At a glance
- Drugs Vascular endothelial growth factor-165 gene therapy (Neovasculgen) (Primary)
- Indications Peripheral nervous system diseases
- Focus Adverse reactions; Therapeutic Use
- Sponsors Human Stem Cells Institute
- 05 Feb 2015 New trial record